Dean Ranasinghe
Dr Wei-Yu Lin
Dr Sarah Fordham
Dr Abrar Alharbi
Dr Nicola Sunter
et al. | Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia | 2026 |
|
Professor Graham Jackson
| Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling | 2026 |
|
Professor Graham Jackson
| The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review | 2026 |
|
Professor Graham Jackson
| Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling | 2025 |
|
Professor Graham Jackson
| Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma | 2025 |
|
Professor Graham Jackson
| Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform | 2025 |
|
Professor Graham Jackson
| Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry | 2024 |
|
Professor Graham Jackson
| Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm | 2024 |
|
Dr Sarah Fordham
Dr Wei-Yu Lin
Dr Helen Blair
Dr Claire Elstob
Dr Hayden Bell
et al. | Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia | 2023 |
|
Professor Graham Jackson
| Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma | 2023 |
|
Professor Graham Jackson
| Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic | 2023 |
|
Professor Graham Jackson
| Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial | 2023 |
|
Professor Graham Jackson
| Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial | 2023 |
|
Professor Graham Jackson
| The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open-label, randomised, phase III trial | 2023 |
|
Dr Wei-yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al. | Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x) | 2022 |
|
